Diabetes mellitus is a chronic metabolic disease with a high incidence worldwide. Glycated hemoglobin (A1C) is the reference test for long-term glucose monitoring and has been shown to be associated with chronic complications of diabetes. However, A1C is not recommended in clinical situations that may affect hemoglobin metabolism.
The glycated albumin (GA) is a test that reflects short-term glycemia and is not influenced by situations that falsely alter A1C levels. Glycated albumin is the higher glycated portion of fructosamine. It is measured by a standardized enzymatic methodology, easy and fast to perform.
Market Dynamics
Increasing adoption of inorganic growth strategies, such as company acquisition by key players in the market to expand their product portfolio is expected to drive the market growth over the forecast period. For instance, in September 2021, EKF, a global medical manufacturer of Point-of-Care and Central Laboratory devices, completed the acquisition of Advanced Diagnostic Laboratory LLC, which is a well-known PCR-focused testing laboratory among the pharmaceutical, biotechnology and medical device communities.
The increasing adoption of organic growth strategies such as product launches by key players in the market to expand product portfolio is expected to drive the market growth over the forecast period. For instance, on 3 January 2023, LifeSpan BioSciences Inc, which is a leading provider of antibodies and reagents launched ELISA Kit-LS-F15522, which is a 96-well enzyme-linked immunosorbent assay (ELISA) for the Quantitative detection of human glycated albumin in samples of plasma and serum.
Key features of the study:
- This report provides in-depth analysis of the global glycated albumin assay market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global glycated albumin assay market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study Asahi Kasei Pharma Corporation, Weldon Biotech, Inc., Abbexa Ltd., Laboratory Corporation of America, Biocompare, EFK Diagnostics, Elabscience Biotechnology Inc., Abbott, Diazyme Laboratories, Inc., Abnova Corporation, BSBE, Maccura Biotechnology Co.,Ltd., LifeSpan BioSciences, Inc., Biomatik, Geno Technology Inc., AMS Biotechnology (Europe) Limited, Epinex Diagnostics Inc., DxGen Corp.
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global glycated albumin assay report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global glycated albumin assay market.
Detailed Segmentation:
- Global Glycated albumin assay Market, By Product Type:
- Human Glycated Albumin Assay
- Animal Glycated Albumin Assay
- Global Glycated albumin assay Market, By Application:
- Diagnostics
- Prediabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Research
- Others
- Global Glycated albumin assay Market, By End User:
- Hospitals
- Diagnostic Centers
- Research Centers
- Others
- Global Glycated albumin assay Market, By Region:
- North America
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Asahi Kasei Pharma Corporation*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Weldon Biotech, Inc.
- Abbexa Ltd.
- Laboratory Corporation of America
- Biocompare
- EFK Diagnostics
- Elabscience Biotechnology Inc.
- Abbott
- Diazyme Laboratories, Inc.
- Abnova Corporation
- BSBE
- Maccura Biotechnology Co.,
- LifeSpan BioSciences, Inc.
- Biomatik
- Geno Technology Inc.
- AMS Biotechnology (Europe) Limited
- Epinex Diagnostics Inc
- DxGen Corp
“*” marked represents similar segmentation in other categories in the respective section.
